Hospital groups said the proposed rule is an important step toward restitution for years of 340B underpayments, but they criticized regulators for proposed rate decreases and a lack of additional interest payments.
CMS to return $9B to 340B hospitals under new plan Read More »
Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA ® ) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN).
Melinta Therapeutics, LLC announced today a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to advance two antibiotics currently FDA-approved for adults, BAXDELA® (delafloxacin) and VABOMERE® (meropenem and vaborbactam), for use in pediatrics.
Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations in the United States.
Race executes global license agreement with City of Hope to access FTO IP Read More »
ReCode Therapeutics announced today the appointment of Erica Jefferson as senior vice president of corporate affairs.
NovaBay® Pharmaceuticals, Inc., a company developing and commercializing high-quality eyecare, skincare and wound care products, announces special pricing on Avenova®-branded products to Amazon prime members during Prime Day 2023, being held July 11-12.
Unleash the power of print providers to help reduce waste, increase efficiency and lower costs.
La humanidad ha demostrado una capacidad asombrosa para diseñar y construir máquinas que desafían los límites de la complejidad y la funcionalidad. Estas maravillas de la ingeniería moderna han transformado nuestra sociedad y han sido fundamentales en el avance de …
Broncus Holding Corporation has completed the first case of registered clinical trials of its targeted lung denervation radiofrequency ablation system.
Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced that it has submitted a first Clinical Trial Application for OTOF-GT to the UK’s Medicines and Healthcare products Regulatory Agency.
